Linked Life Data

6503891

Source:http://linkedlifedata.com/resource/pubmed/id/6503891

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1985-1-18
pubmed:abstractText
19 nondialyzed pediatric patients with chronic renal failure and renal osteodystrophy participated in a 4- year prospective trial of the effects of 25-hydroxycholecalciferol (25-OHD3) in the treatment and prevention of clinical symptoms of renal osteodystrophy. Controversy over the possible deleterious effects of other vitamin D metabolites, namely 1,25-dihydroxycholecalciferol and 1, alpha-hydroxyvitamin D3, led to an examination of the rate of decline in renal function both before and during treatment with 25-OHD3. Serum creatinine and glomerular filtration rates were stable in the patients who completed 2, 3, and 4 years of treatment with 25-OHD3. There was no acceleration in the deterioration of renal function during treatment with 25-OHD3 beyond that which would be expected without vitamin D therapy of any kind. There was an increase in mean serum creatinine after 1 year of treatment because 5 children who entered the study were already in the terminal (accelerated) phase of renal function deterioration. These children completed 1 year of therapy with 25-OHD3.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0378-0392
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
351-8
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1984
pubmed:articleTitle
Effects of 25-OHD3 on renal function in pediatric patients with chronic renal failure.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't